文献速递内脏/肾动脉与血管畸形

基于单中心专科经验的泡沫硬化治疗使用十四烷基硫酸钠作为静脉畸形首选硬化剂的疗效与安全性

Efficacy and safety of foam sclerotherapy with sodium tetradecyl sulfate as preferred sclerosant of venous malformations based on experience from a single specialist center.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-10-31

该单中心研究通过前瞻性数据库纳入2015年1月1日至2019年12月31日接受介入治疗的207例静脉畸形患者,按Puig分型分类,评估以3%十四烷基硫酸钠泡沫硬化治疗为首选方案的疗效与并发症。结果显示154例(74.8%)获得有效结局,仅14例(6.8%)无改善,10例(4.8%)出现并发症,I型病变并发症更多。作者认为该治疗临床有效且安全,对Puig I型和II型最成功。

要点

  • 207例静脉畸形患者中154例(74.8%)获得有效结局,14例(6.8%)无改善。
  • 10例(4.8%)出现血肿、血栓性静脉炎和溃疡等并发症,I型病变并发症更多(P = .030)。
  • I型病变较少接受3%十四烷基硫酸钠泡沫硬化治疗(P ≤ .001),更多接受手术切除(P ≤ .001)。

核心结论

  • 作者认为使用3%十四烷基硫酸钠泡沫硬化治疗的介入方案对静脉畸形患者临床有效且安全,对Puig I型和II型静脉畸形最为成功。

研究设计与样本

  • 单中心专科中心经验,通过前瞻性数据库纳入2015年1月1日至2019年12月31日接受介入治疗(栓塞硬化治疗和/或开放手术)的静脉畸形患者,共207例,按Puig分类分型。

主要发现

  • I型病变接受3%十四烷基硫酸钠泡沫硬化治疗的可能性显著更低(P ≤ .001),接受手术切除的可能性显著更高(P ≤ .001)。
  • 研究期间患者首次手术时,3%十四烷基硫酸钠泡沫体积在所有静脉畸形类型间差异有统计学意义(P ≤ .001),I型患者接受的3%十四烷基硫酸钠体积低于II型和III型。
  • 疗效结局分类在所有静脉畸形类型间差异有统计学意义(P ≤ .001)。
  • 总体仅14例(6.8%)报告疗效无改善,38例(18%)未随访,154例(74.8%)获得某种形式的有效结局。
  • 10例(4.8%)出现血肿、血栓性静脉炎和溃疡等并发症,并发症发生率在各分类间差异有统计学意义(P = .030),I型静脉畸形报告更多并发症。

临床怎么用

  • 原文未据此给出推荐,作者结论认为使用3%十四烷基硫酸钠泡沫硬化治疗的介入方案对静脉畸形患者临床有效且安全,对Puig I型和II型静脉畸形最为成功。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We have assessed the efficacy and safety of interventional therapy for venous malformations (VMs), with foam sclerotherapy as the treatment of choice according to our experience at a single specialist center. METHODS: All the patients with VMs who had undergone interventional therapy (ie, embolo-sclerotherapy and/or open surgery) from January 1, 2015 to December 31, 2019 were identified through a prospective database. The VM types were classified according to the Puig classification. The outcome measures assessed included the efficacy and complications. The former was divided into four groups: no response, mild response, moderate response, and complete response. The complications were defined as any tissue or functional damage, distal embolization, or tissue reaction. The continuous variables were compared using the analysis of variance F test, and discrete variables were analyzed using the χ2 tests. P values < .05 were considered statistically significant. RESULTS: A total of 207 patients were included. Puig type I lesions were significantly less likely to have received foam sclerotherapy using sodium tetradecyl sulfate (STS) 3% (P ≤ .001) and more likely to have been surgically excised (P ≤ .001). At the patient's first procedure during the study period, the volumes of foam STS 3% were significantly different across all types of VM (P ≤ .001). The patients with type I VMs had received a lower volume of STS 3% compared with those with type II and III VMs. The efficacy outcome categories were significantly different across all types of VMs (P ≤ .001). Overall, only 14 patients (6.8%) had reported no improvement in efficacy, and 38 patients (18%) had not attended follow-up. Therefore, 154 patients (74.8%) had experienced some form of efficacious outcome. Ten patients (4.8%) had developed complications such as hematoma, thrombophlebitis, and ulceration. The incidence of complications differed significantly across the categories (P = .030), with more complications reported for those with type I VMs. CONCLUSIONS: We found that intervention with foam sclerotherapy using STS 3% is clinically effective and safe for patients with VMs and was most successful for those with Puig type I and II VMs.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Arasakumar DRB, Pang C, Evans N, et al. Efficacy and safety of foam sclerotherapy with sodium tetradecyl sulfate as preferred sclerosant of venous malformations based on experience from a single specialist center. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 36328136. doi:10.1016/j.jvsv.2022.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。